

## JAST (Journal of Animal Science and Technology) TITLE PAGE

Upload this completed form to website with submission

ARTICLE INFORMATION	Fill in information in each box below
<b>Article Type</b>	Research article
<b>Article Title (within 20 words without abbreviations)</b>	Sex-specific effects of maternal and neonatal vitamin A supplementation on blood variables, growth performance, and gene expression in Hanwoo calves
<b>Running Title (within 10 words)</b>	Sex-specific vitamin A effects in Hanwoo calves
<b>Author</b>	Xue-Cheng Jin <sup>1</sup> , Dong-Qiao Peng <sup>2</sup> , Wang-Yong Jeong <sup>1</sup> , Jun-Hee Lee <sup>1</sup> , Bo-Mi Kim <sup>1</sup> , Danil Kim <sup>3</sup> , Yuan H. Brad Kim <sup>4</sup> , and Hong-Gu Lee <sup>1*</sup>
<b>Affiliation</b>	<sup>1</sup> Department of Animal Science, Konkuk University, Seoul 05029, Republic of Korea <sup>2</sup> College of Animal Science, Jilin University, Changchun 130062, China <sup>3</sup> Farm Animal Clinical Training and Research Center, Institute of Green-Bio Science and Technology, Seoul National University, Pyeongchang 25354, Republic of Korea <sup>4</sup> Department of Animal Sciences, Purdue University, West Lafayette, IN 47907, USA
<b>ORCID (for more information, please visit <a href="https://orcid.org">https://orcid.org</a>)</b>	Xue-Cheng Jin ( <a href="https://orcid.org/0000-0002-2828-2359">https://orcid.org/0000-0002-2828-2359</a> ) Dong-Qiao Peng ( <a href="https://orcid.org/0000-0002-0408-0381">https://orcid.org/0000-0002-0408-0381</a> ) Wang-Yong Jeong Jun-Hee Lee ( <a href="https://orcid.org/0000-0001-6739-6028">https://orcid.org/0000-0001-6739-6028</a> ) Bo-Mi Kim ( <a href="https://orcid.org/0000-0002-0110-9900">https://orcid.org/0000-0002-0110-9900</a> ) Danil Kim ( <a href="https://orcid.org/0000-0002-2426-9122">https://orcid.org/0000-0002-2426-9122</a> ) Yuan H. Brad Kim ( <a href="https://orcid.org/0000-0003-1483-4391">https://orcid.org/0000-0003-1483-4391</a> ) Hong-Gu Lee ( <a href="https://orcid.org/0000-0002-0679-5663">https://orcid.org/0000-0002-0679-5663</a> )
<b>Competing interests</b>	No potential conflict of interest relevant to this article was reported.
<b>Funding sources</b> State funding sources (grants, funding sources, equipment, and supplies). Include name and number of grant if available.	This paper was supported by Konkuk University Researcher Fund in 2024, and also by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1A2B5B02001843).
<b>Acknowledgements</b>	Not applicable.
<b>Availability of data and material</b>	Upon reasonable request, the datasets of this study can be available from the corresponding author.
<b>Authors' contributions</b> Please specify the authors' role using this form.	Conceptualization: Jin XC, Peng DQ, Kim YHB, Lee HG. Formal analysis: Jin XC, Kim BM. Methodology: Jin XC, Lee JH. Resources: Jeong WY. Investigation: Jin XC, Jeong WY, Kim DI. Writing - original draft: Jin XC. Writing - review & editing: Jin XC, Peng DQ, Jeong WY, Lee JH, Kim BM, Kim DI, Kim YHB, Lee HG.
<b>Ethics approval and consent to participate</b>	All experimental procedures in this study were approved by the Institutional Animal Care and Use Committee of Konkuk University (permit number: KU21206), in compliance with the "Guide for the Care and Use of Laboratory Animals."

### CORRESPONDING AUTHOR CONTACT INFORMATION

<b>For the corresponding author (responsible for correspondence, proofreading, and reprints)</b>	<b>Fill in information in each box below</b>
First name, middle initial, last name	Hong-Gu, Lee
Email address – this is where your proofs will be sent	Hglee66@konkuk.ac.kr
Secondary Email address	
Address	Department of Animal Science, Konkuk University, Seoul 05029, Korea
Cell phone number	010-3307-4387
Office phone number	02-450-0523
Fax number	

ACCEPTED

## Abstract

1 While early nutritional programming critically shapes offspring development, the integrated  
2 effects of maternal and neonatal vitamin A (VA) supplementation remain unexplored in beef  
3 cattle. In this study, we demonstrate that combining maternal and neonatal VA supplementation  
4 exerts pronounced sex-specific effects on growth performance, blood variables, hepatic and  
5 skeletal muscle gene expression in Hanwoo calves. Forty-four multiparous Hanwoo cows were  
6 assigned to a maternal control (7,000 IU VA/kg DM) or maternal VA group (20,520 IU VA/kg  
7 DM) from the third month of gestation until parturition. Calves were further assigned to a  
8 neonatal control (17,000 IU/d of VA, until d 60) or VA group (53,000 IU/d of VA, until d 60),  
9 forming a  $2 \times 2$  factorial arrangement within each sex. Maternal VA supplementation increased  
10 ( $p < 0.05$ ) birth weight in female calves, but not males, an effect that persisted through weaning.  
11 It also increased ( $p < 0.01$ ) neonatal red blood cell counts and hemoglobin across sexes. In female  
12 calves, neonatal VA supplementation elevated ( $p < 0.05$ ) serum VA concentration at weaning. In  
13 the liver, significant maternal  $\times$  neonatal interactions ( $p < 0.05$ ) occurred for aldehyde  
14 dehydrogenase 1 family member A1 (*ALDH1A1*) and retinoic acid receptor alpha (*RARA*) in  
15 females, peaking in the dual-supplementation group. In female skeletal muscle, maternal and  
16 neonatal VA upregulated ( $p < 0.05$ ) myogenic factor 5 (*MYF5*). Interactions ( $p < 0.05$ ) for  
17 myogenic differentiation 1 (*MYOD*) and myogenin (*MYOG*) showed that neonatal VA  
18 supplementation upregulated both genes in females from maternal control dams. Maternal VA  
19 supplementation increased ( $p < 0.05$ ) zinc finger protein 423 (*ZNF423*) expression, whereas  
20 neonatal VA supplementation decreased ( $p < 0.05$ ) peroxisome proliferator-activated receptor  
21 gamma (*PPARG*). Male calves showed no significant muscle gene expression effects.  
22 Collectively, these findings suggest that maternal VA supply may enhance the transcriptional  
23 capacity for hepatic retinoic acid (RA) metabolism, with neonatal supplementation potentially  
24 providing additional substrate for this pathway. The associated transcriptional responses in  
25 skeletal muscle appear sexually dimorphic, consistent with a preferential effect on myogenic and  
26 adipogenic gene programs in female offspring.

27  
28 **Keywords:** vitamin A, nutritional programming, sex-specific response, Hanwoo calves, gene  
29 expression

30

## Introduction

Maternal nutrition during gestation can permanently alter offspring development, a phenomenon termed fetal or developmental programming [1]. In beef cattle, maternal nutrient restriction or overnutrition during specific gestational periods has been shown to affect birth weight, postnatal growth, and carcass characteristics of the progeny [2, 3]. The balance between skeletal muscle mass and intramuscular fat deposition is a key determinant of beef quality [4]. The cellular foundation for this balance is largely established during fetal and early postnatal development rather than solely during the finishing phase [2]. These programming effects are not confined to the prenatal period; early postnatal nutritional interventions can further modulate the developmental trajectory established in utero, as tissue-specific progenitor cells remain highly plastic during this stage [5]. Among the various nutrients investigated, micronutrients functioning as signaling molecules or transcriptional regulators have attracted considerable interest due to their capacity to directly influence cell fate decisions during development [6, 7]. However, most studies to date have examined a single developmental stage in isolation, and systematic approaches that integrate prenatal and early postnatal interventions remain limited.

The rationale for targeting specific developmental stages lies in the temporal hierarchy of skeletal muscle and adipose tissue ontogeny in cattle. During early to mid-gestation, primary myogenesis establishes the basic framework of muscle fibers, followed by secondary myogenesis, which determines the final fiber number [8]. Concurrently, multipotent mesenchymal stem/stromal cells residing within the muscle undergo lineage commitment toward myogenic, adipogenic, or fibrogenic fates [9]. This competitive process ultimately dictates the ratio of muscle fibers to intramuscular adipocytes in postnatal muscle [10]. Notably, unlike myofiber number, which is essentially fixed at birth, intramuscular preadipocyte hyperplasia initiates around mid-gestation and continues through approximately 11 to 15 months of postnatal age in cattle [11, 12]. This prolonged developmental timeline provides a substantial window during which adipogenic potential can be modulated [13]. Meanwhile, the early postnatal period is also characterized by active satellite cell proliferation and myofiber hypertrophy [14]. These two successive stages—fetal lineage commitment and early postnatal cellular expansion and differentiation—therefore represent the periods of greatest susceptibility to nutritional signals for both muscle and intramuscular fat development. Identifying a nutrient capable of targeting the cellular events within both stages is a logical strategy for maximizing programming efficiency.

Vitamin A (VA) is a fat-soluble micronutrient essential for embryonic development and cell differentiation [15]. Its bioactive metabolite, retinoic acid (RA), activates nuclear receptors that regulate both myogenic and adipogenic gene expression [16]. Maternal VA supplementation

65 during late gestation has been reported to increase offspring birth weight in beef cattle [17].  
66 Similarly, VA supplementation in neonatal calves [18] and lambs [19] promoted skeletal muscle  
67 development by upregulating myogenic gene expression. Early postnatal oral VA administration  
68 also improved calf growth and modulated intramuscular fat deposition [18, 20]. In our previous *in*  
69 *vitro* study, RA treatment of bovine skeletal muscle-derived cells (BSMCs) promoted myogenic  
70 differentiation, enhanced early preadipocyte lineage commitment, and simultaneously suppressed  
71 terminal adipogenic differentiation [21]. These findings collectively indicate that VA can  
72 influence both muscle and intramuscular fat development across prenatal and postnatal stages.  
73 Existing *in vivo* studies, however, have largely focused on a single developmental stage, and the  
74 factor of sex has rarely been incorporated into experimental designs. Sex hormones can modulate  
75 RA signaling by competing for shared transcriptional co-regulators and altering local retinol  
76 metabolism [22, 23]. Whether integrating VA supplementation across both stages produces  
77 additive or interactive effects on offspring development remains unknown.

78 We hypothesized that combining maternal and neonatal VA supplementation would alter  
79 hepatic RA metabolism in the offspring and modify the transcriptional profiles of myogenic and  
80 adipogenic genes in skeletal muscle, thereby affecting growth performance. Therefore, the  
81 objectives of this study were to evaluate the effects of maternal and neonatal VA supplementation  
82 on growth performance, blood variables, and hepatic and skeletal muscle gene expression in male  
83 and female Hanwoo calves.

84  
85

## 86 **Materials and Methods**

### 87 ***Maternal management and dietary treatments***

88 All experimental procedures in this study were approved by the Institutional Animal Care and  
89 Use Committee of Konkuk University (permit number: KU21206), in compliance with the  
90 “Guide for the Care and Use of Laboratory Animals.” Forty-eight multiparous Hanwoo cows  
91 were stratified by parity ( $2.5 \pm 0.3$ ) and age ( $49.1 \pm 0.6$  months at artificial insemination) and  
92 randomly assigned to either a maternal control ( $n = 24$ ; no supplemental VA) or a maternal VA  
93 group ( $n = 24$ ; supplemental VA). Four cows were subsequently excluded due to abortion or twin  
94 births, resulting in 44 singleton calves available for the study. Cows were housed in pens (four  
95 animals per pen) with *ad libitum* access to water. Artificial insemination was performed by a  
96 technician blinded to treatment allocation, using semen from 15 sires randomly distributed across  
97 treatments. Pregnancy was confirmed by ultrasonography at three months of gestation. Each cow  
98 was offered 3.5 kg/d of commercial concentrate (Jeil Feed Co., Daejeon, Korea) and 10 kg/d of

99 rice straw (as-fed basis), with no orts observed throughout the trial. The basal diet met the  
100 nutrient requirements for gestating beef cows as recommended by the Korean Feeding Standard  
101 for Hanwoo (NIAS, 2022) and Nutrient requirements of beef cattle (NASEM, 2016). Beginning  
102 at three months of gestation, cows in the maternal VA group received retinyl acetate ( $5 \times 10^5$   
103 IU/g, Hanyou Feed, Wuxi, China) as a top dressing mixed with 15 g/d of corn meal as a carrier.  
104 Vitamin A concentrations in the total diet were 7,000 IU/kg DM for the maternal control group  
105 and 20,520 IU/kg DM for the maternal VA group. Supplementation continued until parturition  
106 (duration:  $193.5 \pm 1.5$  d). Daily health checks were conducted, and dry sawdust bedding was  
107 replaced monthly.

108

### 109 ***Calf management and neonatal treatments***

110 Immediately after birth, calves were separated from their dams, weighed, and individually  
111 housed in pens ( $2.0 \times 1.4 \times 1.2$  m; length  $\times$  width  $\times$  height). Within 3 h of birth, all calves were  
112 administered commercial bovine dried colostrum (NurseMate, Brookings, SD, USA; reconstituted  
113 per manufacturer's instructions) via an esophageal tube, ensuring a minimum IgG intake of 175 g.  
114 Calves from each maternal treatment group were then stratified by sex and birth weight ( $32.1 \pm$   
115  $3.4$  kg) and randomly assigned to either the control or VA treatment, producing a  $2 \times 2$  factorial  
116 arrangement (maternal treatment–neonatal treatment) within each sex: CON-CON (CC;  $n = 12$ , 6  
117 males and 6 females), CON-VA (CV;  $n = 11$ , 6 males and 5 females), VA-CON (VC;  $n = 10$ , 5  
118 males and 5 females), and VA-VA (VV;  $n = 11$ , 5 males and 6 females). From d 1 to 30, calves  
119 were fed milk replacer (NurseMate, reconstituted at 160 g/L) using an automated feeder  
120 (CalfRail, Foerster-Technik, Engen, Germany) four times daily (0700, 1100, 1700, and 2100 h).  
121 The allowance was set at 4 L/d from d 1 to 15 and increased to 6.4 L/d from d 16 to 30. At d 31,  
122 calves were relocated to larger individual pens ( $2.0 \times 1.5 \times 1.8$  m) and offered *ad libitum* access  
123 to a mixed ration comprising 80% commercial calf starter (Jeil Feed Co.) and 20% oat hay. Milk  
124 replacer was then bottle-fed manually twice daily (0700 and 1700 h), with the allowance linearly  
125 reduced from 6.4 to 0 L/d by d 61 to achieve complete weaning [24]. Throughout the pre-weaning  
126 period (d 2 to 60), calves in the neonatal VA groups were administered a daily dose of 36,000 IU  
127 water-dispersible retinyl acetate dissolved in 20 mL of water (Hanyou Feed, Wuxi, China) via an  
128 oral syringe after the morning feeding. Consequently, the total daily VA intakes for the neonatal  
129 control and VA groups were 17,000 and 53,000 IU/d, respectively. Water was available *ad*  
130 *libitum* to all calves throughout this period. Dry sawdust bedding was replaced daily. Health  
131 status was monitored daily, and calves presenting with diarrhea received supplemental  
132 commercial electrolyte solution (Kim's Ade, BEBE COW, Icheon, Republic of Korea) between

133 milk feedings to prevent dehydration. Daily dry matter intake (DMI) was recorded individually  
134 throughout the pre-weaning period. Body weight was recorded before the morning feeding on d  
135 61 to determine average daily gain (ADG) and feed efficiency (ADG/DMI).

136

#### 137 ***Chemical composition analysis***

138 Feed samples were analyzed for dry matter (DM), crude protein (CP), ether extract (EE), ash,  
139 neutral detergent fiber (NDF), and acid detergent fiber (ADF). DM was determined by oven-  
140 drying ground samples at 100 °C overnight (AOAC, 1990; method 930.15). Total nitrogen was  
141 quantified by the Kjeldahl method, and CP was derived by multiplying nitrogen content by 6.25  
142 (AOAC, 1990; method 984.13). EE was measured by solvent extraction following AOAC (1990;  
143 method 920.39). Ash concentration was obtained by combustion at 550 °C overnight according to  
144 AOAC (1990; method 942.05). Calcium (Ca) and phosphorus (P) were determined by inductively  
145 coupled plasma spectroscopy (AOAC, 1990; method 985.01). The NDF and ADF fractions were  
146 analyzed using the methodology of Van Soest et al. [26]. Nutritional composition of the  
147 experimental diets is presented in Table 1.

148

#### 149 ***Blood collection and preparation***

150 Blood samples were collected from the jugular vein of calves before the morning feeding (0700  
151 h) at 2 and 61 days of age. Each sample was aliquoted into two types of evacuated blood tubes: a  
152 K2 EDTA tube (BD Vacutainer, Franklin Lakes, NJ, USA) for whole blood and an SST tube (BD  
153 Vacutainer) for serum. Following collection, serum was separated by centrifugation at  $2,700 \times g$   
154 for 15 min at 4 °C and then stored at -80 °C for subsequent analysis of VA concentration and  
155 metabolic profiles. Throughout this process, serum samples were handled under light-protected  
156 conditions to prevent VA degradation. The whole blood was utilized for the complete blood count  
157 (CBC) test.

158

#### 159 ***Complete blood count (CBC)***

160 The CBC test included four parameters, measured using a hematology analyzer (Microsemi  
161 LC-660; HORIBA, Kyoto, Japan). These parameters were: white blood cells (WBC), red blood  
162 cells (RBC), hemoglobin (HGB), and platelets (PLT).

163

#### 164 ***Metabolic profile test (MPT)***

165 The MPT included five items, determined using an automated clinical chemistry analyzer  
166 (FUJI DRI-CHEM 7000i; Fujifilm, Tokyo, Japan). These items comprised serum levels of  
167 glucose (GLU), creatinine, total cholesterol (TCHO), and aspartate transaminase (AST).

168

#### 169 *Serum VA analysis*

170 Serum VA concentration was analyzed using reversed-phase high-performance liquid  
171 chromatography (RP-HPLC), as previously described by Jin et al. [27]. Briefly, serum samples  
172 were deproteinized using ethanol, followed by extraction with hexane. The extracts were then  
173 evaporated under nitrogen gas and reconstituted in 95% methanol, which served as the mobile  
174 phase. Separation of VA was performed using a stainless-steel Nova-Pak C18 column (4- $\mu$ m  
175 reversed-phase column, 150 mm  $\times$  3.9 mm ID, Waters, Dublin, Ireland) in an Agilent 1100 Series  
176 HPLC Value System (Agilent Technologies, Waldbronn, Germany), with UV detection at 325  
177 nm. A standard curve was established using retinol (>99%, Sigma-Aldrich, Saint Louis, MO,  
178 USA) as an external standard with a twofold serial dilution. Retinyl acetate (>99%, Sigma-  
179 Aldrich) was used as an internal standard to correct the results, ensuring a recovery rate of over  
180 80% in all samples. All procedures were performed under red light to prevent the degradation of  
181 VA, and butylated hydroxytoluene (BHT, Sigma-Aldrich) was used as a stabilizer for sample  
182 preparation. Each sample was analyzed in duplicate.

183

#### 184 *Longissimus lumborum muscle and liver biopsy*

185 *Longissimus lumborum* muscle and liver samples were collected from each calf at 65 days of  
186 age through biopsy procedures carried out by a veterinarian. The area around the biopsy site was  
187 shaved and locally anesthetized with 2% lidocaine (Jeil Pharmaceutical, Yongin, Gyeonggi,  
188 Republic of Korea). Approximately 2 g of muscle sample was collected from the right lumbar  
189 region between the 3rd and 4th lumbar vertebrae (L3-L4) using blunt-ended scissors. The sample  
190 was transferred into a 5 mL diethyl pyrocarbonate (DEPC)-treated microtube for mRNA  
191 quantification. Approximately 0.4 g of liver sample was obtained through the right 9th and 10th  
192 intercostal spaces using an Achieve coaxial biopsy system (14 G, 15 cm, CareFusion, San Diego,  
193 CA, USA), and then transferred into a 2 mL DEPC-treated microtube. Once the samples were  
194 placed in the microtubes, they were immediately flash-frozen in liquid nitrogen and transported to  
195 the laboratory on dry ice. For subsequent analysis, the frozen samples were stored at  $-80^{\circ}\text{C}$ .

196

#### 197 *Total RNA isolation and cDNA synthesis*

198 Total RNA was extracted from 0.1 g each of muscle and liver samples, with the muscle tissue  
199 being ground to a fine powder in liquid nitrogen. The prepared samples were then homogenized  
200 in TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) using an IKA T10 basic  
201 ULTRA-TURRAX disperser (IKA Werke GmbH & Co. KG, Staufen, Germany) equipped with a  
202 dispersing tool S10N-5G (IKA Werke). The extraction was then performed following the  
203 manufacturer's protocol. Briefly, phase separation was achieved by adding chloroform, and the  
204 aqueous phase containing RNA was collected. RNA was precipitated with isopropanol, washed  
205 with 75% ethanol, air-dried, and reconstituted in DEPC-treated water. The concentration and  
206 purity of the RNA were measured on a NanoDrop 1000 Spectrophotometer (Thermo Fisher  
207 Scientific, Waltham, MA, USA). The 260/280 ratio of the RNA samples used in this study was in  
208 the range of 1.8–2.0. RNA integrity was measured using an RNA Nano 6000 assay kit (Agilent  
209 Technologies) on an Agilent Bioanalyzer 2100 system (Agilent Technologies). The RNA  
210 integrity number (RIN) of the samples used in this study was  $8.9 \pm 0.5$ . cDNA was synthesized  
211 from 1  $\mu\text{g}$  of RNA using a cDNA synthesis kit (AccuPower CycleScript RT PreMix, Bioneer,  
212 Seoul, Republic of Korea) on a T100 Thermal Cycler (Bio-Rad, Hercules, CA, USA).

213

#### 214 ***Quantitative real-time PCR (qPCR)***

215 The qPCR reactions were performed using a SYBR green kit (AccuPower 2X GreenStar qPCR  
216 MasterMix, Bioneer) on a CFX Connect Real-Time PCR Detection System (Bio-Rad) with a final  
217 primer concentration of 100 nM. Specific primers spanning exon-exon junctions were designed  
218 within coding sequences (CDS) using Primer-BLAST  
219 (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) to avoid amplification of potential genomic  
220 DNA in the samples. Primers were synthesized by Bioneer via the AccuOligo system. All primers  
221 were validated using no-template controls and melt curve analysis to confirm both amplification  
222 specificity and the absence of primer-dimer formation. The amplification efficiencies were  
223 calculated from standard curves generated using 10-fold serial dilutions and were above 95%.  
224 The primer sequences and annealing temperatures are provided in Table S1. Gene expression data  
225 were normalized to the geometric mean of three reference genes: eukaryotic translation initiation  
226 factor 3 subunit K (*EIF3K*), ribosomal protein lateral stalk subunit P0 (*RPLP0*), and ribosomal  
227 protein S9 (*RPS9*) [28]. The resulting  $\Delta\text{CT}$  values were subjected to statistical analyses, whereas  
228 relative expression levels were calculated using the  $2^{-\Delta\Delta\text{CT}}$  method [29] and expressed as fold  
229 changes for presentation.

230

#### 231 ***Statistical analysis***

232 All data were analyzed using the GLM procedure in SAS 9.4 (SAS Institute Inc., Cary, NC,  
233 USA). Birth weight and neonatal blood variables (hematological parameters, serum metabolites,  
234 and VA concentration) were analyzed with maternal treatment, sex, and their interaction as fixed  
235 effects. Because a significant maternal treatment  $\times$  sex interaction was detected for birth weight,  
236 all subsequent analyses were stratified by sex. For each sex, growth performance, weaning blood  
237 variables, and post-weaning hepatic and skeletal muscle mRNA expression were analyzed with  
238 maternal treatment, neonatal treatment, and their interaction as fixed effects. Residual normality  
239 was verified via the Shapiro–Wilk test, and Levene’s test was used to confirm homogeneity of  
240 variances. Post hoc pairwise comparisons were conducted using the Tukey–Kramer test.  
241 Statistical significance was declared at  $p < 0.05$ , and a tendency was considered at  $0.05 \leq p <$   
242  $0.10$ .

## 244 Results

### 245 *Birth weight and neonatal blood variables*

246 At birth, a significant main effect of sex ( $p < 0.05$ ) and a maternal treatment  $\times$  sex interaction  
247 ( $p < 0.05$ ) were observed for birth weight (**Table 2**). Specifically, regardless of the maternal  
248 treatment, male calves had higher birth weights than female calves. Furthermore, female calves  
249 born to cows in the maternal control group exhibited significantly lower ( $p < 0.05$ ) birth weights  
250 compared with all other groups. Regarding hematological parameters, calves born to cows  
251 supplemented with VA during gestation exhibited significantly greater ( $p < 0.05$ ) RBC and HGB  
252 compared with those in the maternal control group. However, WBC and PLT did not differ  
253 significantly ( $p > 0.05$ ) among the groups. For serum metabolites, a significant maternal  
254 treatment  $\times$  sex interaction ( $p < 0.05$ ) was detected for creatinine concentration. Female calves in  
255 the maternal VA group had significantly higher ( $p < 0.05$ ) creatinine levels than female calves in  
256 the maternal control group. Additionally, maternal VA supplementation resulted in significantly  
257 higher ( $p < 0.05$ ) serum VA concentrations in newborn calves, regardless of sex. Finally, GLU,  
258 TCHO, and AST did not differ significantly ( $p > 0.05$ ) between groups.

### 259 *Growth performance from birth to weaning*

260 Regarding pre-weaning growth performance, maternal and neonatal VA supplementation did  
261 not significantly affect ( $p > 0.05$ ) birth weight, weaning weight, ADG, DMI, or feed efficiency in  
262 male calves (**Table 3**). For female calves, those born to cows supplemented with VA during  
263 gestation had significantly greater ( $p < 0.05$ ) birth weights and weaning weights than those in the  
264

265 maternal control group. However, ADG, DMI, and feed efficiency did not differ significantly ( $p$   
266  $> 0.05$ ) among the treatments.

267

### 268 ***Hematological parameters at weaning***

269 At weaning, maternal and neonatal VA supplementation did not significantly affect ( $p > 0.05$ )  
270 hematological parameters, including WBC, RBC, HGB, and PLT, in either male or female calves  
271 (Table 4).

272

### 273 ***Serum metabolites and VA concentration at weaning***

274 Regarding serum metabolites at weaning, no significant differences ( $p > 0.05$ ) were observed  
275 in the concentrations of GLU, creatinine, TCHO, or AST among the treatments for both sexes  
276 (Table 5). Furthermore, serum VA concentration in male calves was not significantly ( $p > 0.05$ )  
277 affected by the treatments. However, in female calves, neonatal VA supplementation resulted in  
278 significantly higher ( $p < 0.05$ ) serum VA concentrations compared with the neonatal control  
279 group.

280

### 281 ***Hepatic mRNA expression of VA-related genes***

282 The relative mRNA expression of VA metabolism-related genes in the liver post-weaning,  
283 neonatal VA supplementation tended to increase ( $p = 0.058$ ) the expression of aldehyde  
284 dehydrogenase 1 family member A1 (*ALDH1A1*) in male calves, while other genes were not  
285 significantly affected ( $p > 0.05$ ) (Table 6). In female calves, however, both maternal and neonatal  
286 VA supplementation significantly increased ( $p < 0.01$ ) *ALDH1A1* expression. Furthermore,  
287 significant maternal  $\times$  neonatal treatment interactions ( $p < 0.05$ ) were observed for both  
288 *ALDH1A1* and retinoic acid receptor alpha (*RARA*). Specifically, female calves in the VA-VA  
289 group exhibited significantly higher expression levels of both *ALDH1A1* and *RARA* compared  
290 with all other groups. Additionally, maternal VA supplementation significantly increased ( $p <$   
291  $0.05$ ) the expression of retinol binding protein 4 (*RBP4*). The expression of alcohol  
292 dehydrogenase 1C (*ADH1C*) did not differ significantly ( $p > 0.05$ ) among the treatments.

293

### 294 ***Skeletal muscle mRNA expression of myogenic genes***

295 For the relative mRNA expression of myogenic and adipogenic genes in the *Longissimus*  
296 *lumborum* muscle, treatments did not significantly affect ( $p > 0.05$ ) the expression of any  
297 evaluated genes in male calves (Table 7). In female calves, significant maternal treatment  $\times$   
298 neonatal treatment interactions ( $p < 0.05$ ) were observed for the myogenic genes myogenic

299 differentiation 1 (*MYOD*) and myogenin (*MYOG*). Specifically, female calves in the CON-VA  
300 group had significantly higher ( $p < 0.05$ ) expression of both *MYOD* and *MYOG* than those in the  
301 CON-CON group. Additionally, both maternal and neonatal VA supplementation significantly  
302 increased ( $p < 0.05$ ) the expression of myogenic factor 5 (*MYF5*). Furthermore, the expression of  
303 the adipogenic gene zinc finger protein 423 (*ZNF423*) in female calves was significantly  
304 increased ( $p < 0.05$ ) by maternal VA supplementation, whereas neonatal VA supplementation  
305 significantly decreased ( $p < 0.05$ ) the expression of peroxisome proliferator activated receptor  
306 gamma (*PPARG*). Finally, the expression of paired box 7 (*PAX7*), myogenic factor 6 (*MYF6*),  
307 preadipocyte factor-1 (*PREF1*), CCAAT/enhancer-binding protein beta (*CEBPB*), and fatty acid  
308 binding protein 4 (*FABP4*) did not differ significantly ( $p > 0.05$ ).

309

310

## Discussion

311 This study aimed to investigate the effects of combined vitamin A (VA) supplementation  
312 during gestation and the pre-weaning period on early growth performance, blood parameters, and  
313 mRNA expression related to hepatic metabolism and skeletal muscle development in Hanwoo  
314 cattle. Based on our prior findings regarding late gestation [17] and the neonatal calf period [18],  
315 the VA supplementation level for cows in the current study was set at three times that of the  
316 control group, which corresponds to approximately seven times the level recommended by  
317 NASEM (2016) for gestating beef cows (2,800 IU/kg DM). Similarly, the VA intake for neonatal  
318 calves was three times that of the control, equating to roughly five times the adequate intake  
319 (approximately 10,000 IU/d) suggested by NASEM (2021) for milk replacer-fed calves.  
320 Hematological and serum biochemical parameters of calves measured at both birth and post-  
321 weaning remained within normal reference ranges, confirming the *in vivo* safety of the high-dose  
322 supplementation regimen employed in this study.

323 Previous studies have reported that maternal VA supplementation can influence offspring  
324 growth and development. In goats, VA supplementation during late gestation increased offspring  
325 birth weight [32]. Similarly, our previous study found that late-gestational VA supplementation  
326 increased birth weight in Hanwoo calves [17]. However, that study lacked a balanced sex ratio,  
327 which limited the assessment of sex-specific effects. In the present study, we found that the effect  
328 of maternal VA supplementation on calf birth weight was sex-dependent. Specifically, maternal  
329 VA selectively increased the birth weight of female calves to a level comparable to that of males,  
330 without affecting male calves. Interestingly, the interaction pattern for serum creatinine at birth  
331 mirrored this finding, with elevated levels observed only in female calves from VA-supplemented  
332 dams. Serum creatinine primarily originates from the non-enzymatic degradation of

333 phosphocreatine in skeletal muscle and can partially reflect the muscle mass of animals [33, 34].  
334 Therefore, this result may provide indirect biochemical support for enhanced fetal skeletal muscle  
335 accretion in female calves. However, neonatal serum creatinine may also be influenced by  
336 residual placental clearance [35], and this interpretation should be treated with caution.  
337 Additionally, maternal VA supplementation significantly increased RBC counts and HGB levels  
338 in neonates regardless of sex. This is consistent with findings of Moosavian et al. [36], suggesting  
339 that improved maternal VA status may enhance neonatal oxygen-carrying capacity by promoting  
340 fetal erythropoiesis [37]. Notably, the birth weight advantage in female calves from VA-  
341 supplemented dams persisted through the weaning period. However, no significant differences in  
342 ADG or feed efficiency were detected among treatment groups. This indicates that the weaning-  
343 stage weight advantage likely originated from a higher initial birth weight rather than accelerated  
344 postnatal growth. Similarly, direct VA supplementation to neonatal calves had no significant  
345 effect on growth performance in either sex. This may be partly explained by the relatively short  
346 supplementation period under the early weaning system (2 months of age) employed in this study.  
347 Furthermore, potential weaning-associated stress could have attenuated the growth-promoting  
348 effects of VA supplementation during this period [38].

349 The effective delivery of maternal VA to the offspring is a prerequisite for evaluating the  
350 efficacy of gestational nutritional interventions. In this study, maternal VA supplementation  
351 significantly increased serum VA (retinol) concentrations in neonatal calves regardless of sex,  
352 confirming effective placental transfer of maternal VA and a consequent improvement in fetal  
353 circulating VA status. This finding is consistent with previous reports in beef cattle [17] and goats  
354 [32]. However, by weaning, the serum VA response pattern diverged between sexes. While no  
355 significant differences in serum VA concentrations were observed among treatment groups in  
356 male calves, neonatal VA supplementation significantly elevated serum VA levels at weaning in  
357 female calves. This discrepancy suggests that inherent physiological differences may exist  
358 between sexes in VA absorption, retention, or peripheral tissue clearance.

359 The liver is the central organ for VA metabolism, responsible for oxidizing circulating retinol  
360 into biologically active retinoic acid (RA) and regulating its distribution to peripheral tissues [39].  
361 Consistent with the serum VA response patterns, the expression of hepatic VA metabolism-  
362 related genes also exhibited pronounced sex specificity. Male calves showed lower sensitivity to  
363 VA supplementation, with only a tendency for upregulated *ALDH1A1* expression in response to  
364 neonatal VA supplementation. In female calves, the elevated serum VA concentration at weaning  
365 was driven by neonatal VA supplementation. However, the mRNA expression of *RBP4*, which is  
366 responsible for transporting hepatic retinol into the circulation [40], was significantly upregulated

367 only by maternal VA supplementation. This discordance between transcriptional levels and  
368 circulating metabolite profiles suggests that maternal VA may have exerted a lasting metabolic  
369 programming effect on the fetal liver [41], potentially altering its capacity to mobilize and export  
370 VA during the pre-weaning period. Furthermore, *ALDH1A1*, the rate-limiting enzyme catalyzing  
371 the irreversible oxidation of retinal to RA [42], and *RARA*, the nuclear receptor mediating RA-  
372 dependent transcriptional regulation [43], both exhibited significant maternal  $\times$  postnatal  
373 interactions in female calves, with the highest expression observed in the dual-supplementation  
374 group (VV). This result is consistent with the possibility that maternal VA intervention primed  
375 the hepatic RA metabolic network at the transcriptional level, with combined maternal and  
376 neonatal supplementation associated with the highest expression of these key components. The  
377 relatively large within-group variation observed for *ALDH1A1* expression in the VV group likely  
378 reflects individual differences in baseline hepatic VA reserves and in the responsiveness of the  
379 hepatic RA metabolic network to dual VA stimulation. In contrast, no significant differences in  
380 *ADHIC* expression were detected among treatment groups, possibly because this enzyme  
381 primarily participates in the reversible oxidation of retinol to retinal rather than the rate-limiting  
382 step of RA synthesis [44].

383 Given the sex-specific activation patterns of the hepatic RA metabolic network, we further  
384 examined the expression profiles of myogenic genes in skeletal muscle. In female calves, the  
385 expression of the early myogenic determinant *MYF5* [45] was significantly upregulated by both  
386 maternal and neonatal VA. Maternal VA supplementation in this study commenced at the third  
387 month of gestation, which falls within the active phase of secondary myogenesis in bovine  
388 fetuses, reported to extend from approximately 60 to 180 days post-conception [46]. Therefore,  
389 the upregulation of *MYF5* may reflect an expanded pool of myogenic progenitor cells established  
390 during fetal development [47]. This partly explains the significantly higher birth weight observed  
391 in female calves from VA-supplemented dams. Additionally, *MYOD* and *MYOG*, both involved  
392 in myogenic differentiation [48], exhibited significant maternal  $\times$  neonatal interactions.  
393 Specifically, neonatal VA supplementation alone (CV group) significantly increased the  
394 expression of both genes compared to the un-supplemented control (CC group). One possible  
395 explanation is that skeletal muscle tissue not previously exposed to high maternal VA (CV group)  
396 displayed a more pronounced transcriptional response to neonatal VA supplementation. In  
397 contrast, skeletal muscle that had been exposed to elevated maternal VA (VV group) may have  
398 undergone adaptive regulation, thereby attenuating its responsiveness during the pre-weaning  
399 period. Unlike the prenatal period for myofiber formation, intramuscular adipogenesis is a  
400 continuous process that extends well into the postnatal phase [11]. In this study, maternal VA

401 supplementation significantly upregulated *ZNF423*, a mediator of early adipogenic lineage  
402 commitment in intramuscular preadipocyte progenitors [49]. This suggests that gestational  
403 supplementation may have promoted the commitment and recruitment of adipogenic progenitor  
404 cells. Conversely, neonatal VA supplementation downregulated the expression of *PPARG*, a core  
405 transcription factor for terminal adipocyte differentiation [50], potentially reflecting a modest  
406 delay in the differentiation program. The combination of maternal-stage upregulation of  
407 adipogenic potential and neonatal-stage suppression of terminal differentiation suggests, at the  
408 transcriptional level, that VA supplementation may have the potential to expand the intramuscular  
409 preadipocyte pool in offspring.

410 In the present study, male calves showed no significant response of the examined genes to VA  
411 supplementation in post-weaning biopsies, although the modest per-sex sample size precludes  
412 detection of smaller effects. The limited transcriptional responsiveness in males may attenuate the  
413 potential for downstream phenotypic differences. One possible explanation for this sex-specific  
414 responsiveness lies in the crosstalk between sex hormones and RA signaling pathways [22]. It  
415 has been reported that the androgen receptor can antagonize the transcriptional activity of RAR  
416 through mechanisms such as competition for co-activators [23]. Accordingly, the continuous  
417 secretion of endogenous androgens by male calves during the pre-weaning period may have  
418 systemically suppressed VA-induced transcriptional signaling. Conversely, RA metabolism in  
419 skeletal muscle has been shown to exhibit marked sexual dimorphism. A recent study using an  
420 *Rdh10* haplodeficient mouse model revealed that estrogen can specifically induce the expression  
421 of alternative retinol dehydrogenases, thereby maintaining local RA homeostasis in skeletal  
422 muscle when the primary biosynthetic pathway is compromised [51]. In the absence of androgen-  
423 mediated antagonism, female calves may possess greater metabolic flexibility through similar  
424 estrogen-regulated networks, enabling a more efficient conversion of exogenous VA into RA  
425 signaling and the amplification of its transcriptional effects. A notable limitation, however, is that  
426 long-term productive outcomes were not assessed in female cattle. Future research should  
427 incorporate extended follow-ups of female cattle to determine whether the hepatic and skeletal  
428 muscle transcriptional changes observed at weaning can ultimately translate into functional  
429 phenotypic outcomes. A further consideration concerns the timing of tissue sampling. Although  
430 biopsies were performed four days after weaning, the genes examined in this study are not  
431 established direct targets of the stress response, and substantial residual effects of weaning-  
432 associated stress on these measurements are unlikely.

433

434

## Acknowledgments

435 Not applicable.

436

437

438

## References

439

440

1. Barker DJ. The fetal and infant origins of adult disease. *British Medical Journal*.

441

1990;301(6761):1111–. <https://doi.org/10.1136/bmj.301.6761.1111>

442

2. Du M, Tong J, Zhao J, Underwood KR, Zhu M, Ford SP, et al. Fetal programming of skeletal muscle development in ruminant animals1. *Journal of Animal Science*.

443

2010;88(suppl\_13):E51–E60. <https://doi.org/10.2527/jas.2009-2311>

444

3. Funston RN, Larson DM, Vonnahme KA. Effects of maternal nutrition on conceptus growth and offspring performance: Implications for beef cattle production1. *Journal of Animal Science*. 2010;88(suppl\_13):E205–E15. <https://doi.org/10.2527/jas.2009-2351>

447

448

4. Hocquette JF, Gondret F, Baéza E, Médale F, Jurie C, Pethick DW. Intramuscular fat content in meat-producing animals: development, genetic and nutritional control, and identification of putative markers. *Animal*. 2010;4(2):303–19.

450

451

<https://doi.org/10.1017/S1751731109991091>

452

5. Carlberg C, Velleuer E. Nutrition and epigenetic programming. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2023;26(3).

453

454

<https://doi.org/10.1097/MCO.0000000000000900>

455

6. Wu G, Bazer FW, Cudd TA, Meininger CJ, Spencer TE. Maternal Nutrition and Fetal Development. *The Journal of Nutrition*. 2004;134(9):2169–72.

456

457

<https://doi.org/10.1093/jn/134.9.2169>

458

7. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: The second decade. *Cell*. 1995;83(6):835–9.

459

460

[https://doi.org/10.1016/0092-8674\(95\)90199-X](https://doi.org/10.1016/0092-8674(95)90199-X)

461

8. Bonnet M, Cassar-Malek I, Chilliard Y, Picard B. Ontogenesis of muscle and adipose tissues and their interactions in ruminants and other species. *Animal*. 2010;4(7):1093–109. <https://doi.org/10.1017/S1751731110000601>

462

463

464

9. Uezumi A, Fukada S-i, Yamamoto N, Takeda Si, Tsuchida K. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle.

465

466

*Nature Cell Biology*. 2010;12(2):143–52. <https://doi.org/10.1038/ncb2014>

467

10. Du M, Huang Y, Das AK, Yang Q, Duarte MS, Dodson MV, et al. MEAT SCIENCE

468

AND MUSCLE BIOLOGY SYMPOSIUM: Manipulating mesenchymal progenitor cell

- 469 differentiation to optimize performance and carcass value of beef cattle<sup>1,2</sup>. *Journal of*  
470 *Animal Science*. 2013;91(3):1419–27. <https://doi.org/10.2527/jas.2012-5670>
- 471 11. Cianzio DS, Topel DG, Whitehurst GB, Beitz DC, Self HL. Adipose Tissue Growth and  
472 Cellularity: Changes in Bovine Adipocyte Size and Number. *Journal of Animal Science*.  
473 1985;60(4):970–6. <https://doi.org/10.2527/jas1985.604970x>
- 474 12. Symonds ME, Pope M, Sharkey D, Budge H. Adipose tissue and fetal programming.  
475 *Diabetologia*. 2012;55(6):1597–606. <https://doi.org/10.1007/s00125-012-2505-5>
- 476 13. Hausman GJ, Dodson MV, Ajuwon K, Azain M, Barnes KM, Guan LL, et al. BOARD-  
477 INVITED REVIEW: The biology and regulation of preadipocytes and adipocytes in meat  
478 animals<sup>1,2</sup>. *Journal of Animal Science*. 2009;87(4):1218–46.  
479 <https://doi.org/10.2527/jas.2008-1427>
- 480 14. Yin H, Price F, Rudnicki MA. Satellite Cells and the Muscle Stem Cell Niche.  
481 *Physiological Reviews*. 2013;93(1):23–67. <https://doi.org/10.1152/physrev.00043.2011>
- 482 15. Clagett-Dame M, DeLuca HF. The role of vitamin A in mammalian reproduction and  
483 embryonic development. *Annual Review of Nutrition*. 2002; 22:347–81.  
484 <https://doi.org/10.1146/annurev.nutr.22.010402.102745E>
- 485 16. Peng DQ, Smith SB, Lee HG. Vitamin A regulates intramuscular adipose tissue and  
486 muscle development: promoting high-quality beef production. *Journal of Animal Science*  
487 *and Biotechnology*. 2021;12(1):34. <https://doi.org/10.1186/s40104-021-00558-2>
- 488 17. Jo YH, Peng DQ, Kim WS, Kim SJ, Kim NY, Kim SH, et al. The effects of vitamin A  
489 supplementation during late-stage pregnancy on longissimus dorsi muscle tissue  
490 development, birth traits, and growth performance in postnatal Korean native calves.  
491 *Asian-Australas J Anim Sci*. 2020;33(5):742–52. <https://doi.org/10.5713/ajas.19.0413>
- 492 18. Peng DQ, Jo YH, Kim SJ, Kim NY, Nejad JG, Lee HG. Oral vitamin A supplementation  
493 during neonatal stage enhances growth, pre-adipocyte and muscle development in Korean  
494 native calves. *Animal Feed Science and Technology*. 2020;268:114609.  
495 <https://doi.org/10.1016/j.anifeedsci.2020.114609>
- 496 19. Song P, Chen X, Zhao J, Li Q, Li X, Wang Y, et al. Vitamin A injection at birth improves  
497 muscle growth in lambs. *Animal Nutrition*. 2023;14:204–12.  
498 <https://doi.org/10.1016/j.aninu.2023.05.011>
- 499 20. Peng DQ, Kim SJ, Lee HG. Metabolomics analyses to characterize metabolic alterations  
500 in Korean native calves by oral vitamin A supplementation. *Scientific Reports*.  
501 2020;10(1):8092. <https://doi.org/10.1038/s41598-020-65023-y>

- 502 21. Jin XC, Peng DQ, Kim WS, Park JS, Lee JH, Kim YHB, et al. All-trans retinoic acid  
503 drives development phase-specific response to adipogenic and myogenic processes in  
504 bovine skeletal muscle-derived cells. *Meat and Muscle Biology*. 2024;8(1).  
505 <https://doi.org/10.22175/mmb.16978>
- 506 22. Napoli JL. Retinoic Acid: Sexually Dimorphic, Anti-Insulin and Concentration-  
507 Dependent Effects on Energy. *Nutrients*. 2022;14(8):1553.  
508 <https://doi.org/10.3390/nu14081553>
- 509 23. Huang HFS, Li M-t, Von Hagen S, Zhang YF, Irwin RJ. Androgen Modulation of the  
510 Messenger Ribonucleic Acid of Retinoic Acid Receptors in the Prostate, Seminal  
511 Vesicles, and Kidney in the Rat\*. *Endocrinology*. 1997;138(2):553–9.  
512 <https://doi.org/10.1210/endo.138.2.4945>
- 513 24. Welboren AC, Leal LN, Steele MA, Khan MA, Martín-Tereso J. Performance of ad  
514 libitum fed dairy calves weaned using fixed and individual methods. *Animal*.  
515 2019;13(9):1891–8. <https://doi.org/10.1017/S1751731119000181>
- 516 25. AOAC. *Official Methods of Analysis*. 15th Edition ed. Washington DC.: Association of  
517 Official Analytical Chemist; 1990.
- 518 26. Van Soest PJ, Robertson JB, Lewis BA. Methods for Dietary Fiber, Neutral Detergent  
519 Fiber, and Nonstarch Polysaccharides in Relation to Animal Nutrition. *Journal of Dairy*  
520 *Science*. 1991;74(10):3583–97. [https://doi.org/10.3168/jds.S0022-0302\(91\)78551-2](https://doi.org/10.3168/jds.S0022-0302(91)78551-2)
- 521 27. Jin XC, Peng DQ, Kim SJ, Kim NY, Nejad JG, Kim D, et al. Vitamin A supplementation  
522 downregulates ADH1C and ALDH1A1 mRNA expression in weaned beef calves.  
523 *Animal Nutrition*. 2022;10:372–81. <https://doi.org/10.1016/j.aninu.2022.06.007>
- 524 28. Wang G-H, Liang C-C, Li B-Z, Du X-Z, Zhang W-Z, Cheng G, et al. Screening and  
525 validation of reference genes for qRT-PCR of bovine skeletal muscle-derived satellite  
526 cells. *Scientific Reports*. 2022;12(1):5653. <https://doi.org/10.1038/s41598-022-09476-3>
- 527 29. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time  
528 Quantitative PCR and the 2- $\Delta\Delta$ CT Method. *Methods*. 2001;25(4):402–8.  
529 <https://doi.org/10.1006/meth.2001.1262>
- 530 30. National Academies of Sciences E, Medicine. *Nutrient Requirements of Beef Cattle:*  
531 *Eighth Revised Edition*. Washington, DC: The National Academies Press; 2016. 494 p.  
532 <https://doi.org/10.17226/19014>
- 533 31. National Academies of Sciences E, Medicine. *Nutrient Requirements of Dairy Cattle:*  
534 *Eighth Revised Edition*. Washington, DC: The National Academies Press; 2021. 502 p.  
535 <https://doi.org/10.17226/25806>

- 536 32. Abd Eldaim MA, Gaafar KM, Darwish RA, Mahboub HD, Helal MA. Prepartum vitamin  
537 A supplementation enhances goat doe health status and kid viability and performance.  
538 Small Ruminant Research. 2015;129:6–10.  
539 <https://doi.org/10.1016/j.smallrumres.2015.06.007>
- 540 33. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, et al.  
541 Influence of Muscle Mass and Physical Activity on Serum and Urinary Creatinine and  
542 Serum Cystatin C. *Clinical Journal of the American Society of Nephrology*.  
543 2008;3(2):348–54. <https://doi.org/10.2215/cjn.02870707>
- 544 34. Wuthier PR, Stratton PO. The Creatinine Level of Blood Serum as an Indicator of  
545 Carcass Composition. *Journal of Animal Science*. 1957;16(4):961–6.  
546 <https://doi.org/10.2527/jas1957.164961x>
- 547 35. Probo M, Giordano A, Moretti P, Opsomer G, Fiems L, Paltrinieri S, et al. Serum  
548 biochemical profile in Holstein Friesian and Belgian blue calves in the first 48 hours of  
549 life. *Italian Journal of Animal Science*. 2019;18(1):657–62.  
550 <https://doi.org/10.1080/1828051X.2018.1551073>
- 551 36. Moosavian HR, Mohri M, Seifi HA. Effects of parenteral over-supplementation of  
552 vitamin A and iron on hematology, iron biochemistry, weight gain, and health of neonatal  
553 dairy calves. *Food and Chemical Toxicology*. 2010;48(5):1316–20.  
554 <https://doi.org/10.1016/j.fct.2010.02.030>
- 555 37. Semba RD, Bloem MW. The anemia of vitamin A deficiency: epidemiology and  
556 pathogenesis. *European Journal of Clinical Nutrition*. 2002;56(4):271–81.  
557 <https://doi.org/10.1038/sj.ejcn.1601320>
- 558 38. Arthington JD, Spears JW, Miller DC. The effect of early weaning on feedlot  
559 performance and measures of stress in beef calves<sup>1,2</sup>. *Journal of Animal Science*.  
560 2005;83(4):933–9. <https://doi.org/10.2527/2005.834933x>
- 561 39. Ross AC, Zolfaghari R. Regulation of Hepatic Retinol Metabolism: Perspectives from  
562 Studies on Vitamin A Status. *The Journal of Nutrition*. 2004;134(1):269S–75S.  
563 <https://doi.org/10.1093/jn/134.1.269S>
- 564 40. Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin  
565 A in human plasma. *The Journal of Clinical Investigation*. 1968;47(9):2025–44.  
566 <https://doi.org/10.1172/JCI105889>
- 567 41. Srinivasagan R, Galmés S, Vasileva D, Rubí P, Palou A, Amengual J, et al. Maternal  
568 genetics and diet modulate vitamin A homeostasis of the offspring and affect the  
569 susceptibility to obesity in adulthood in mice. *American Journal of Physiology-*

- 570 Endocrinology and Metabolism. 2024;327(3):E258–E70.  
571 <https://doi.org/10.1152/ajpendo.00116.2024>
- 572 42. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxidases: genetics, evolution and  
573 biochemistry. *Cellular and Molecular Life Sciences*. 2008;65(7):1019–48.  
574 <https://doi.org/10.1007/s00018-007-7398-y>
- 575 43. Chambon P. A decade of molecular biology of retinoic acid receptors. *The FASEB*  
576 *Journal*. 1996;10(9):940–54. <https://doi.org/10.1096/fasebj.10.9.8801176>
- 577 44. Höög J-O, Hedberg JJ, Strömberg P, Svensson S. Mammalian Alcohol Dehydrogenase –  
578 Functional and Structural Implications. *Journal of Biomedical Science*. 2001;8(1):71–6.  
579 <https://doi.org/10.1159/000054015>
- 580 45. Rudnicki MA, Schnegelsberg PNJ, Stead RH, Braun T, Arnold H-H, Jaenisch R. MyoD  
581 or Myf-5 is required for the formation of skeletal muscle. *Cell*. 1993;75(7):1351–9.  
582 [https://doi.org/10.1016/0092-8674\(93\)90621-V](https://doi.org/10.1016/0092-8674(93)90621-V)
- 583 46. Russell RG, Oteruelo FT. An ultrastructural study of the differentiation of skeletal muscle  
584 in the bovine fetus. *Anatomy and Embryology*. 1981;162(4):403–17.  
585 <https://doi.org/10.1007/BF00301866>
- 586 47. Bentzinger CF, Wang YX, Rudnicki MA. Building Muscle: Molecular Regulation of  
587 Myogenesis. *Cold Spring Harbor Perspectives in Biology*. 2012;4(2).  
588 <https://doi.org/10.1101/cshperspect.a008342>
- 589 48. Tapscott SJ. The circuitry of a master switch: MyoD and the regulation of skeletal muscle  
590 gene transcription. *Development*. 2005;132(12):2685–95.  
591 <https://doi.org/10.1242/dev.01874>
- 592 49. Gupta RK, Arany Z, Seale P, Mepani RJ, Ye L, Conroe HM, et al. Transcriptional control  
593 of preadipocyte determination by Zfp423. *Nature*. 2010;464(7288):619–23.  
594 <https://doi.org/10.1038/nature08816>
- 595 50. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPAR $\gamma$  Is  
596 Required for the Differentiation of Adipose Tissue In Vivo and In Vitro. *Molecular Cell*.  
597 1999;4(4):611–7. [https://doi.org/10.1016/S1097-2765\(00\)80211-7](https://doi.org/10.1016/S1097-2765(00)80211-7)
- 598 51. Zhao Y, Vuckovic M, Yoo HS, Fox N, Rodriguez A, McKessy K, et al. Retinoic acid  
599 exerts sexually dimorphic effects on muscle energy metabolism and function. *Journal of*  
600 *Biological Chemistry*. 2021;297(3). <https://doi.org/10.1016/j.jbc.2021.101101>
- 601 52. National Research Council. Nutrient requirements of dairy cattle: Seventh Revised  
602 Edition. Washington, DC: National Academies Press; 2001.  
603 <https://doi.org/10.17226/9825>

- 604 53. Kim U-H, Lee S-H, Cho S-R, Kang S-S, Jin S, Ahn J-S, et al. Hematological Changes  
605 and Reference Intervals in Hanwoo Calves during the First 28 Weeks of Life. *Animals*.  
606 2021;11(6):1806. <https://doi.org/10.3390/ani11061806>
- 607 54. Yu K, Canalias F, Solà-Oriol D, Arroyo L, Pato R, Saco Y, et al. Age-Related Serum  
608 Biochemical Reference Intervals Established for Unweaned Calves and Piglets in the  
609 Post-weaning Period. *Frontiers in Veterinary Science*. 2019;6.  
610 <https://doi.org/10.3389/fvets.2019.00123>
- 611 55. Roadknight NW, Courtman NF, Mansell PD, Jongman EC, Loh ZA, Fisher AD.  
612 Biochemistry and hematology reference intervals for neonatal dairy calves aged 5-  
613 12 days. *Veterinary Clinical Pathology*. 2021;50(2):278–86.  
614 <https://doi.org/10.1111/vcp.12955>
- 615 56. Kazana P, Siachos N, Panousis N, Kalaitzakis E, Arsenos G, Valergakis GE. Effect of  
616 weaning on serum biochemistry and establishment of reference intervals for peri-weaning  
617 period of Holstein calves. *Livestock Science*. 2021;250:104550.  
618 <https://doi.org/10.1016/j.livsci.2021.104550>

619

620

## Tables and Figures

621 **Table 1. Nutritional composition of the experimental diets**

Item <sup>1</sup> (% DM)	Dam	Calf	
	Basal diet	Milk replacer	Mixed ration
DM, % as-fed	85.84	95.52	90.25
CP	10.68	24.22	21.31
NDF	50.30	-	25.77
ADF	34.28	-	12.44
EE	3.03	17.24	2.87
Ash	9.58	6.87	6.93
NFC <sup>2</sup>	26.41	51.68	43.12
Ca	0.54	0.85	0.78
P	0.24	0.68	0.55

622 <sup>1</sup>DM, dry matter; CP, crude protein; EE, ether extract; NDF, neutral detergent fiber; ADF, acid detergent  
 623 fiber; NFC, non-fiber carbohydrate; Ca, calcium; P, phosphorus.

624 <sup>2</sup>Non-fiber carbohydrates (%) = 100 - (CP + EE + NDF + Ash) [52]

625

ACCEPTED

626  
627

**Table 2. Effects of maternal VA supplementation on birth weight and blood variables of newborn calves**

Item <sup>1</sup>	Maternal control		Maternal VA		SEM	<i>p</i> -value		
	Male	Female	Male	Female		VA	Sex	VA × Sex
<b>Birth weight, kg</b>	33.4 <sup>a</sup>	28.9 <sup>b</sup>	32.9 <sup>a</sup>	32.7 <sup>a</sup>	0.54	0.108	0.019	0.033
<b>Hematological parameters (Reference values<sup>2</sup>)</b>								
WBC, × 10 <sup>3</sup> /μL (4.6–16.4)	8.7	8.4	8.8	9.0	0.31	0.578	0.667	0.357
RBC, × 10 <sup>6</sup> /μL (6.8–14.6)	9.9	9.7	10.5	10.9	0.21	0.007	0.675	0.837
HGB, g/dL (6.5–13.5)	9.8	9.9	11.1	11.9	0.29	0.005	0.483	0.726
PLT, × 10 <sup>3</sup> /μL (166.0–918.0)	433.0	381.6	421.4	412.0	13.91	0.419	0.122	0.169
<b>Serum metabolites</b>								
GLU, mg/dL (75.30–193.30)	87.60	84.00	76.70	91.10	4.03	0.452	0.326	0.984
Creatinine, mg/dL (0.93–1.65)	1.12 <sup>ab</sup>	1.09 <sup>b</sup>	1.13 <sup>ab</sup>	1.34 <sup>a</sup>	0.06	0.393	0.638	0.042
TCHO, mg/dL (20.80–67.50)	35.90	42.18	42.20	36.80	2.22	0.920	0.923	0.204
AST, U/L (49.6–133.4)	45.50	52.90	45.50	51.70	2.09	0.887	0.115	0.884
<b>Serum VA, IU/dL</b>	20.59	23.58	29.39	28.26	1.34	0.011	0.715	0.422

628  
629

<sup>1</sup>WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; PLT, platelets; GLU, glucose; TCHO, total cholesterol; AST, aspartate transaminase; VA, vitamin A.

630  
631

<sup>2</sup>The reference values for hematological parameters and neonatal serum metabolites were obtained from Kim et al. [53] and Yu et al. [54], respectively.

632  
633

<sup>a,b</sup>Values with different letters are significantly different ( $p < 0.05$ ).

634  
635

**Table 3. Effects of maternal and neonatal VA supplementation on the pre-weaning growth performance of calves**

Item <sup>1</sup>	Treatment				SEM	p-value		
	CC	CV	VC	VV		Mat	Neo	Mat × Neo
<b>Male calves</b>								
Birth weight, kg	33.2	33.7	32.7	33.1	0.70	0.735	0.763	0.967
Weaning weight, kg	59.8	61.5	59.8	56.1	1.17	0.278	0.659	0.274
ADG, g/d	444.1	462.4	452.2	382.3	15.44	0.260	0.415	0.171
DMI, g/d	801.3	880.2	790.6	760.8	20.87	0.579	0.335	0.648
Feed efficiency, g gain/g of DM	0.6	0.6	0.6	0.5	0.01	0.849	0.815	0.754
<b>Female calves</b>								
Birth weight, kg	30.6	27.9	31.4	32.3	0.73	0.036	0.447	0.153
Weaning weight, kg	56.1	53.1	58.1	63.4	1.45	0.045	0.924	0.194
ADG, g/d	425.0	420.2	445.0	518.7	15.09	0.205	0.568	0.476
DMI, g/d	776.1	769.5	767.2	820.2	23.13	0.382	0.619	0.525
Feed efficiency, g gain/g of DM	0.5	0.6	0.6	0.6	0.01	0.957	0.827	0.891

636  
637  
638

<sup>1</sup>ADG, average daily gain; DMI, dry matter intake; CC, CON-CON; CV, CON-VA; VC, VA-CON; VV, VA-VA; Mat, maternal treatment; Neo, neonatal treatment.

639 **Table 4. Effects of maternal and neonatal VA supplementation on hematological parameters of**  
 640 **calves at weaning**

Item <sup>1</sup> (Reference values <sup>2</sup> )	Treatment				SEM	<i>p</i> -value		
	CC	CV	VC	VV		Mat	Neo	Mat × Neo
<b>Male calves</b>								
WBC, × 10 <sup>3</sup> /μL (4.6–16.4)	9.1	9.3	8.9	9.9	0.51	0.320	0.464	0.227
RBC, × 10 <sup>6</sup> /μL (6.8–14.6)	13.6	13.8	14.1	13.5	0.28	0.643	0.126	0.512
HGB, g/dL (6.5–13.5)	13.5	12.9	12.8	13.1	0.35	0.279	0.696	0.807
PLT, × 10 <sup>3</sup> /μL (166–918)	780.5	705.5	690.9	733.7	28.69	0.578	0.554	0.388
<b>Female calves</b>								
WBC, × 10 <sup>3</sup> /μL (4.6–16.4)	10.5	8.9	8.9	10.2	0.68	0.901	0.915	0.358
RBC, × 10 <sup>6</sup> /μL (6.8–14.6)	13.7	14.7	13.7	13.9	0.29	0.625	0.507	0.629
HGB, g/dL (6.5–13.5)	12.6	13.2	12.7	12.4	0.37	0.687	0.840	0.581
PLT, × 10 <sup>3</sup> /μL (166–918)	718.0	699.7	773.3	743.2	35.46	0.581	0.791	0.312

641 <sup>1</sup>WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; PLT, platelets; CC, CON-CON; CV,  
 642 CON-VA; VC, VA-CON; VV, VA-VA; Mat, maternal treatment; Neo, neonatal treatment.

643 <sup>2</sup>The reference values for each item were obtained from [53].  
 644

645 **Table 5. Effects of maternal and neonatal VA supplementation on serum metabolites and VA**  
 646 **concentration of calves at weaning**

Item <sup>1</sup> (Reference values <sup>2</sup> )	Treatment				SEM	<i>p</i> -value		
	CC	CV	VC	VV		Mat	Neo	Mat × Neo
<b>Male calves</b>								
GLU, mg/dL (50.44–124.31)	64.00	61.50	70.40	69.75	3.73	0.376	0.847	0.910
Creatinine, mg/dL (0.57–1.23)	0.87	0.85	0.99	0.96	0.03	0.117	0.441	0.845
TCHO, mg/dL (56.30–158.40)	67.50	68.83	69.80	69.50	5.40	0.903	0.966	0.947
AST, U/L (36.19–105.81)	102.33	83.00	88.75	98.33	8.38	0.547	0.775	0.190
VA, IU/dL	69.70	69.60	77.13	74.08	1.89	0.153	0.694	0.713
<b>Female calves</b>								
GLU, mg/dL (50.44–124.31)	73.20	68.40	53.67	72.00	4.13	0.372	0.447	0.202
Creatinine, mg/dL (0.57–1.23)	0.86	0.92	0.84	0.94	0.03	0.533	0.182	0.357
TCHO, mg/dL (56.30–158.40)	84.25	73.00	68.00	84.00	6.05	0.272	0.281	0.250
AST, U/L (36.19–105.81)	81.00	82.75	70.20	86.40	6.32	0.796	0.520	0.603
VA, IU/dL	56.44	85.74	57.14	88.93	5.94	0.857	0.010	0.908

647 <sup>1</sup>GLU, glucose; TCHO, total cholesterol; AST, aspartate transaminase; VA, vitamin A; CC, CON-CON;  
 648 CV, CON-VA; VC, VA-CON; VV, VA-VA; Mat, maternal treatment; Neo, neonatal treatment.

649 <sup>2</sup>The reference values for GLU and creatinine were obtained from Roadknight et al. [55], and those for  
 650 TCHO and AST from Kazana et al. [56].

651

652 **Table 6. Effects of maternal and neonatal VA supplementation on the relative mRNA expression**  
 653 **of VA metabolism-related genes in the liver of calves post-weaning**

Item <sup>1</sup>	Treatment				<i>p</i> -value		
	CC	CV	VC	VV	Mat	Neo	Mat × Neo
<b>Male calves</b>							
<i>ADH1C</i>	1.00 ± 0.12	1.12 ± 0.16	1.20 ± 0.13	0.88 ± 0.09	0.825	0.873	0.576
<i>ALDH1A1</i>	1.00 ± 0.19	1.46 ± 0.30	1.55 ± 0.39	2.56 ± 1.61	0.299	0.058	0.283
<i>RBP4</i>	1.00 ± 0.12	1.00 ± 0.11	0.99 ± 0.14	1.13 ± 0.31	0.897	0.829	0.855
<i>RARA</i>	1.00 ± 0.09	0.89 ± 0.07	1.08 ± 0.19	0.92 ± 0.26	0.914	0.907	0.966
<b>Female calves</b>							
<i>ADH1C</i>	1.00 ± 0.14	0.94 ± 0.04	0.99 ± 0.05	0.92 ± 0.08	0.901	0.892	0.956
<i>ALDH1A1</i>	1.00 ± 0.31 <sup>b</sup>	1.53 ± 0.29 <sup>b</sup>	1.83 ± 1.00 <sup>b</sup>	11.56 ± 5.57 <sup>a</sup>	0.008	0.007	0.029
<i>RBP4</i>	1.00 ± 0.07	1.24 ± 0.12	1.68 ± 0.25	2.12 ± 0.39	0.019	0.121	0.428
<i>RARA</i>	1.00 ± 0.01 <sup>b</sup>	1.01 ± 0.08 <sup>b</sup>	1.18 ± 0.12 <sup>b</sup>	1.67 ± 0.38 <sup>a</sup>	0.044	0.315	0.036

654 <sup>1</sup>*ADH1C*, alcohol dehydrogenase 1C; *ALDH1A1*, aldehyde dehydrogenase 1 family member A1; *RBP4*,  
 655 retinol binding protein 4; *RARA*, retinoic acid receptor alpha; CC, CON-CON; CV, CON-VA; VC, VA-  
 656 CON; VV, VA-VA; Mat, maternal treatment; Neo, neonatal treatment.

657 Values are expressed as fold change ± SEM relative to the CC group.

658 <sup>a,b</sup>Values with different letters are significantly different (*p* < 0.05).

659

660  
661

**Table 7. Effects of maternal and neonatal VA supplementation on the relative mRNA expression of myogenic and adipogenic genes in the *Longissimus lumborum* muscle of calves post-weaning**

Item <sup>1</sup>	Treatment				<i>p</i> -value		
	CC	CV	VC	VV	Mat	Neo	Mat × Neo
<b>Male calves</b>							
<i>Myogenesis</i>							
<i>PAX7</i>	1.00 ± 0.05	0.89 ± 0.08	0.86 ± 0.16	0.83 ± 0.08	0.928	0.937	0.571
<i>MYF5</i>	1.00 ± 0.13	0.76 ± 0.17	0.69 ± 0.14	0.84 ± 0.19	0.713	0.691	0.662
<i>MYOD</i>	1.00 ± 0.39	1.34 ± 0.14	1.77 ± 0.30	1.14 ± 0.24	0.889	0.810	0.419
<i>MYOG</i>	1.00 ± 0.30	1.35 ± 0.06	1.46 ± 0.24	1.38 ± 0.15	0.805	0.799	0.808
<i>MYF6</i>	1.00 ± 0.12	1.20 ± 0.16	1.10 ± 0.28	1.48 ± 0.52	0.714	0.524	0.485
<i>Adipogenesis</i>							
<i>PREF1</i>	1.00 ± 0.11	1.10 ± 0.27	0.86 ± 0.20	0.77 ± 0.20	0.505	0.684	0.407
<i>ZNF423</i>	1.00 ± 0.14	0.80 ± 0.09	0.91 ± 0.13	1.11 ± 0.22	0.680	0.837	0.778
<i>CEBPB</i>	1.00 ± 0.13	0.85 ± 0.06	0.90 ± 0.28	0.66 ± 0.13	0.913	0.323	0.846
<i>PPARG</i>	1.00 ± 0.17	0.87 ± 0.09	0.87 ± 0.11	0.92 ± 0.06	0.985	0.904	0.895
<i>FABP4</i>	1.00 ± 0.34	1.23 ± 0.71	1.09 ± 0.58	0.88 ± 0.46	0.869	0.957	0.834
<b>Female calves</b>							
<i>Myogenesis</i>							
<i>PAX7</i>	1.00 ± 0.16	1.53 ± 0.08	1.65 ± 0.29	1.48 ± 0.13	0.542	0.820	0.711
<i>MYF5</i>	1.00 ± 0.26	2.05 ± 0.18	1.98 ± 0.40	2.47 ± 0.36	0.033	0.019	0.296
<i>MYOD</i>	1.00 ± 0.50 <sup>b</sup>	4.74 ± 0.87 <sup>a</sup>	2.96 ± 0.57 <sup>ab</sup>	2.91 ± 0.16 <sup>ab</sup>	0.616	0.040	0.014
<i>MYOG</i>	1.00 ± 0.39 <sup>b</sup>	3.25 ± 0.47 <sup>a</sup>	2.41 ± 0.31 <sup>ab</sup>	2.17 ± 0.22 <sup>ab</sup>	0.455	0.038	0.027
<i>MYF6</i>	1.00 ± 0.24	1.04 ± 0.32	0.88 ± 0.28	1.65 ± 0.59	0.119	0.304	0.157
<i>Adipogenesis</i>							
<i>PREF1</i>	1.00 ± 0.30	1.06 ± 0.27	1.23 ± 0.19	0.71 ± 0.11	0.816	0.836	0.404
<i>ZNF423</i>	1.00 ± 0.25	1.49 ± 0.13	1.62 ± 0.05	1.86 ± 0.21	0.047	0.178	0.235
<i>CEBPB</i>	1.00 ± 0.22	1.38 ± 0.24	1.02 ± 0.22	1.07 ± 0.42	0.460	0.299	0.763
<i>PPARG</i>	1.00 ± 0.09	0.62 ± 0.07	0.74 ± 0.12	0.67 ± 0.07	0.728	0.034	0.564
<i>FABP4</i>	1.00 ± 0.34	1.06 ± 0.23	1.08 ± 0.34	1.68 ± 0.70	0.667	0.818	0.870

662 <sup>1</sup>*PAX7*, paired box 7; *MYF5*, myogenic factor 5; *MYOD*, myogenic differentiation 1; *MYOG*, myogenin;  
 663 *MYF6*, myogenic factor 6; *PREF1*, preadipocyte factor-1; *ZNF423*, zinc finger protein 423; *CEBPB*,  
 664 CCAAT/enhancer-binding protein beta; *PPARG*, peroxisome proliferator activated receptor gamma;  
 665 *FABP4*, fatty acid binding protein 4; CC, CON-CON; CV, CON-VA; VC, VA-CON; VV, VA-VA; Mat,  
 666 maternal treatment; Neo, neonatal treatment.

667 Values are expressed as fold change ± SEM relative to the CC group.

668 <sup>a,b</sup>Values with different letters are significantly different (*p* < 0.05).

669

670

671

672